Fresenius Medical Care (FME) Stock Overview
Provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
FME Community Fair Values
Create NarrativeSee what 36 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fresenius Medical Care AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €41.93 |
| 52 Week High | €47.86 |
| 52 Week Low | €34.57 |
| Beta | 0.82 |
| 1 Month Change | 5.70% |
| 3 Month Change | 4.77% |
| 1 Year Change | -9.36% |
| 3 Year Change | -10.37% |
| 5 Year Change | -39.93% |
| Change since IPO | 155.93% |
Recent News & Updates
Narrative Update • Jun 28
FME: Buybacks And Digital Dialysis Platform Will Support Future Returns
The latest analyst update on Fresenius Medical Care trims the price target by about €1, reflecting a slightly higher discount rate along with adjusted assumptions for revenue, profit margin and future P/E expectations. What’s in the News for Fresenius Medical Care Fresenius Medical Care is highlighted alongside DaVita in recent coverage of the global dialysis market.
Narrative Update • Jun 14
FME: Value Based Kidney Care Success Will Drive Long Term Upside
Analysts have trimmed their price target for Fresenius Medical Care to about €64 from roughly €65, reflecting updated views on fair value, a higher discount rate, more muted revenue growth assumptions, slightly lower profit margin expectations and a reduced future P/E multiple. What's in the News Interwell Health, Fresenius Medical Care's value based care segment, reported top quality scores in the CMS Kidney Care Choices Model and delivered $273 million in shared savings over three years, highlighting performance in value based kidney care (source: Interwell Health news release).
Narrative Update • May 31
FME: Higher Discount Rate And Flat 2026 Outlook Will Pressure Returns
Analysts have trimmed their price target on Fresenius Medical Care from €32.00 to €31.00, citing updated assumptions on discount rates, modest revenue growth and profit margins, and a slightly lower future P/E multiple. What's in the News Fresenius Medical Care presented new research at the European Renal Association Congress 2026, highlighting work in hemodiafiltration, real world dialysis outcomes, artificial intelligence support tools and a high precision large language model approach for screening research abstracts (Key Developments).Recent updates
Narrative Update • Jun 28
FME: Buybacks And Digital Dialysis Platform Will Support Future Returns
The latest analyst update on Fresenius Medical Care trims the price target by about €1, reflecting a slightly higher discount rate along with adjusted assumptions for revenue, profit margin and future P/E expectations. What’s in the News for Fresenius Medical Care Fresenius Medical Care is highlighted alongside DaVita in recent coverage of the global dialysis market.Narrative Update • Jun 14
FME: Value Based Kidney Care Success Will Drive Long Term Upside
Analysts have trimmed their price target for Fresenius Medical Care to about €64 from roughly €65, reflecting updated views on fair value, a higher discount rate, more muted revenue growth assumptions, slightly lower profit margin expectations and a reduced future P/E multiple. What's in the News Interwell Health, Fresenius Medical Care's value based care segment, reported top quality scores in the CMS Kidney Care Choices Model and delivered $273 million in shared savings over three years, highlighting performance in value based kidney care (source: Interwell Health news release).Narrative Update • May 31
FME: Higher Discount Rate And Flat 2026 Outlook Will Pressure Returns
Analysts have trimmed their price target on Fresenius Medical Care from €32.00 to €31.00, citing updated assumptions on discount rates, modest revenue growth and profit margins, and a slightly lower future P/E multiple. What's in the News Fresenius Medical Care presented new research at the European Renal Association Congress 2026, highlighting work in hemodiafiltration, real world dialysis outcomes, artificial intelligence support tools and a high precision large language model approach for screening research abstracts (Key Developments).Analysis Article • May 14
Fresenius Medical Care's (ETR:FME) Earnings Offer More Than Meets The Eye
Fresenius Medical Care AG's ( ETR:FME ) recent earnings report didn't offer any surprises, with the shares unchanged...Analysis Article • May 09
Earnings Miss: Fresenius Medical Care AG Missed EPS By 60% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that Fresenius Medical Care AG ( ETR:FME ) filed its first-quarter result this time...Narrative Update • May 01
FME: Flat 2026 Guidance And Rich P/E Will Pressure Returns
Analysts have kept their price target for Fresenius Medical Care steady at €32.00, citing only small adjustments to assumptions for discount rate, revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News Humacyte realigned ex U.S. rights to Symvess, an acellular tissue engineered vessel, through an amendment to its distribution agreement with Fresenius Medical Care.Narrative Update • Apr 17
FME: Dividend Growth And Buybacks Will Support Future Shareholder Returns
Analysts have adjusted their price target for Fresenius Medical Care slightly to €44.71, reflecting updated assumptions on the discount rate, modest revenue growth expectations, profit margin outlook, and future P/E levels. What's in the News Fresenius Medical Care AG proposed a dividend of €1.49 per share for the 2025 financial year, described as a 3% increase and equivalent to a 33% payout of adjusted net income (Key Developments).Narrative Update • Apr 03
FME: Rich P E Will Clash With Slowing Margins And Earnings Reset
Analysts have narrowed their price target framework for Fresenius Medical Care to around €32, reflecting updated views on a slightly higher discount rate, softer revenue growth and margin expectations, and a higher assumed future P/E multiple. What's in the News New 2026 outlook: revenue expected to be broadly flat versus 2025, with operating income guided to a range between a positive and negative mid single digit % change at constant currency, excluding special items, off a 2025 base of €19,628m revenue and €2,212m operating income (Company guidance).Narrative Update • Mar 19
FME: Confirmed 2025 Outlook And Dividend Policy Will Support Shareholder Returns
Analysts have nudged their price target for Fresenius Medical Care slightly lower to about €44.71 from roughly €45.06, citing updated assumptions for revenue growth, profit margins and a somewhat higher future P/E multiple. What's in the News Planned dividend proposal for fiscal 2025 is €1.49 per share, which the company describes as a 3% increase and equal to a 33% payout of adjusted net income (Key Developments).Narrative Update • Mar 05
FME: Confirmed 2025 Earnings Outlook Will Support Shareholder Returns Upside Potential
Analysts have trimmed their price target for Fresenius Medical Care slightly to €45.06 from €45.12. This reflects updated views on the discount rate, revenue growth, profit margin assumptions, and a lower expected future P/E multiple.Narrative Update • Feb 19
FME: Confirmed 2025 Guidance And Margin Progress Will Support Future Upside Potential
Analysts have nudged their price target for Fresenius Medical Care slightly lower to about €45, from roughly €47. This reflects updated assumptions for a modestly different growth outlook, a small adjustment to the discount rate, and a marginally higher profit margin paired with a slightly lower future P/E.Analysis Article • Feb 09
Returns On Capital Signal Difficult Times Ahead For Fresenius Medical Care (ETR:FME)
If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...Narrative Update • Feb 05
FME: Earnings Reset Will Clash With Rich P E And Margin Headwinds
Analysts have lowered their price target for Fresenius Medical Care from €35.00 to €32.00, citing updated views on discount rates, revenue growth, profit margins and future P/E assumptions. What's in the News Fresenius Medical Care AG confirmed its earnings guidance for 2025, giving investors clearer visibility on management’s current expectations (Key Developments).Narrative Update • Jan 22
FME: Earnings Reset And Buyback Activity Will Support A Stable Outlook
Analysts have trimmed their fair value estimate for Fresenius Medical Care from €38.00 to €35.00, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Fresenius Medical Care confirmed its 2025 earnings guidance, indicating it expects to be at the very top end of its revenue growth range for the year, alongside operating income growth guidance in the high-teens to high 20s range.Narrative Update • Jan 07
FME: Share Repurchases And Margin Progress Will Support Future Upside Potential
Analysts have nudged their price target for Fresenius Medical Care slightly higher to €47.21 from €47.10, citing refined assumptions around discount rates, revenue growth, profit margins and future P/E multiples that leave their overall valuation view largely unchanged. What's in the News Completed share buyback tranche from July 1, 2025 to September 30, 2025, with 3,564,523 shares repurchased for €151.78 million, equal to 1.21% of shares under the program announced on June 17, 2025 (company announcement).Narrative Update • Dec 24
FME: Share Repurchases Will Support Future Earnings Recovery And Upside Potential
Narrative Update Analysts have modestly trimmed their price target on Fresenius Medical Care from $47.41 to $47.10, citing slightly softer expectations for revenue growth and profit margins that are only partly offset by a marginally lower discount rate and a higher assumed future P E multiple. What's in the News Completed a share repurchase tranche of 3,564,523 shares, equal to 1.21% of share capital, for €151.78 million under the June 17, 2025 buyback program (company disclosure) Confirmed fiscal 2025 outlook calling for positive to low single digit revenue growth from a 2024 base of €19.34 billion (company guidance) Expects 2025 operating income, excluding special items and at constant currency, to grow in the high teens to high twenties percent from a 2024 base of €1.80 billion (company guidance) Valuation Changes Fair Value: reduced slightly from €47.41 to €47.10 per share, reflecting modestly softer expectations.Analysis Article • Dec 15
Fresenius Medical Care AG (ETR:FME) Doing What It Can To Lift Shares
It's not a stretch to say that Fresenius Medical Care AG's ( ETR:FME ) price-to-earnings (or "P/E") ratio of 15.9x...Narrative Update • Dec 10
FME: Share Repurchases And Margin Recovery Will Drive Future Upside Momentum
Analysts have trimmed their average price target for Fresenius Medical Care slightly, from approximately $47.88 to $47.41, reflecting modestly higher perceived discount rates and marginally softer expectations for long term growth and profitability. What's in the News Issued fiscal 2025 guidance calling for positive to low single digit revenue growth from a 2024 base of EUR 19,336 million, highlighting a cautious top line outlook amid market and reimbursement pressures (company guidance) Forecasts operating income excluding special items to grow at a high teens to high twenties percentage rate in 2025 from a 2024 base of EUR 1,797 million, indicating ongoing margin recovery and efficiency gains (company guidance) Completed a share buyback tranche between July 1 and September 30, 2025, repurchasing 3,564,523 shares, or 1.21% of outstanding share capital, for EUR 151.78 million under the June 17, 2025 program (company announcement) Valuation Changes The Fair Value Estimate has edged down slightly from $47.88 to $47.41 per share.Narrative Update • Nov 26
FME: Share Repurchase And Margin Gains Will Support Upside Momentum
Analysts have slightly reduced their price target for Fresenius Medical Care from $48.06 to $47.88, citing marginal adjustments in financial forecasts. What's in the News From July 1, 2025 to September 30, 2025, Fresenius Medical Care completed the repurchase of 3,564,523 shares, representing 1.21% of shares, for €151.78 million.Narrative Update • Nov 11
FME: Share Buyback And Margin Expansion Will Drive Future Upside
Analysts have lowered their price target for Fresenius Medical Care from $49.03 to $48.06. They cite slight adjustments to projected discount rates and earnings multiples, even as improvements in revenue growth and profit margins are expected.Analysis Article • Nov 07
Fresenius Medical Care AG Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Shareholders might have noticed that Fresenius Medical Care AG ( ETR:FME ) filed its quarterly result this time last...Analysis Article • Nov 04
Is Fresenius Medical Care AG (ETR:FME) Potentially Undervalued?
Let's talk about the popular Fresenius Medical Care AG ( ETR:FME ). The company's shares saw a double-digit share price...Narrative Update • Oct 28
Aging Demographics And Home Care Trends Will Shape Future Profit Opportunities
Analysts have slightly reduced their price target for Fresenius Medical Care from $49.74 to $49.03, citing modest adjustments to revenue growth forecasts and future profit margins. What's in the News Fresenius Medical Care AG issued new earnings guidance for fiscal 2025, expecting revenue growth to achieve a positive to low-single digit percent rate compared to the previous year (Key Developments).Analysis Article • Oct 20
Capital Allocation Trends At Fresenius Medical Care (ETR:FME) Aren't Ideal
If we're looking to avoid a business that is in decline, what are the trends that can warn us ahead of time? Businesses...Narrative Update • Oct 14
Aging Demographics And Home Dialysis Solutions Will Transform Care Delivery
Analysts have slightly reduced their fair value estimate for Fresenius Medical Care to approximately $49.74 from $50.26. This change reflects marginal adjustments in growth projections and risk assumptions.Analysis Article • Sep 23
Is Fresenius Medical Care (ETR:FME) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Narrative Update • Sep 04
Aging Demographics And Home Dialysis Solutions Will Transform Care Delivery
Fresenius Medical Care's key valuation metrics, including the future P/E ratio and consensus revenue growth forecasts, remained effectively unchanged, resulting in a stable analyst price target of €50.26. What's in the News Fiscal 2025 guidance forecasts positive to low-single digit revenue growth and high-teens to high-twenties percent operating income growth (excluding special items).Analysis Article • Aug 23
A Piece Of The Puzzle Missing From Fresenius Medical Care AG's (ETR:FME) Share Price
There wouldn't be many who think Fresenius Medical Care AG's ( ETR:FME ) price-to-earnings (or "P/E") ratio of 19.4x is...Analysis Article • Aug 08
Fresenius Medical Care AG Just Missed EPS By 81%: Here's What Analysts Think Will Happen Next
XTRA:FME 1 Year Share Price vs Fair Value Explore Fresenius Medical Care's Fair Values from the Community and select...
New Narrative • Nov 18
Strategic Innovations And Cost Efficiency Propel Growth In Global Healthcare Markets
Strategic focus on operational performance and cost savings initiatives is anticipated to enhance operating margins and improve earnings.Shareholder Returns
| FME | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 2.0% | 0.6% | -2.5% |
| 1Y | -9.4% | -1.3% | -0.6% |
Return vs Industry: FME underperformed the German Healthcare industry which returned -2.6% over the past year.
Return vs Market: FME underperformed the German Market which returned -1.3% over the past year.
Price Volatility
| FME volatility | |
|---|---|
| FME Average Weekly Movement | 4.8% |
| Healthcare Industry Average Movement | 5.2% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: FME has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FME's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 108,165 | Helen Giza | www.freseniusmedicalcare.com |
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments.
Fresenius Medical Care AG Fundamentals Summary
| FME fundamental statistics | |
|---|---|
| Market cap | €11.15b |
| Earnings (TTM) | €944.68m |
| Revenue (TTM) | €19.36b |
11.8x
P/E Ratio0.6x
P/S RatioIs FME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FME income statement (TTM) | |
|---|---|
| Revenue | €19.36b |
| Cost of Revenue | €14.33b |
| Gross Profit | €5.02b |
| Other Expenses | €4.08b |
| Earnings | €944.68m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 04, 2026
| Earnings per share (EPS) | 3.55 |
| Gross Margin | 25.96% |
| Net Profit Margin | 4.88% |
| Debt/Equity Ratio | 53.2% |
How did FME perform over the long term?
See historical performance and comparisonDividends
3.6%
Current Dividend Yield45%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/12 01:20 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fresenius Medical Care AG is covered by 38 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olav Zilian | Baader Helvea Equity Research |
| Benjamin Mayo | Baird |
| Robert Bate | Barclays |